Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 4/26/24 → 4/26/26 |
Funding
- DalCor Pharmaceuticals Canada Incorporated: $11,550.00
DAL-302 (dal-GenE-2) Trial: A Phase 3, Double-Blind, Randomized Placebo Controlled Study To Evaluate The Effects Of Dalcetrapib On CV Risk In A Genetically Defined Population With Recent ACS
- Kotter, John (PI)